Separately, Zacks Investment Research upgraded Check Cap from a hold rating to a buy rating and set a $3.75 price target on the stock in a report on Monday, August 6th.
CHEK stock traded down $0.25 during trading on Tuesday, hitting $3.64. The company had a trading volume of 13,528 shares. Check Cap has a one year low of $3.08 and a one year high of $19.78.
An institutional investor recently bought a new position in Check Cap stock. Fosun International Ltd purchased a new position in shares of Check Cap Ltd (NASDAQ:CHEK) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 127,558 shares of the medical research company’s stock, valued at approximately $517,000. Fosun International Ltd owned approximately 7.97% of Check Cap as of its most recent filing with the SEC. Hedge funds and other institutional investors own 17.41% of the company’s stock.
Check Cap Company Profile
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Further Reading: Are Wall Street analysts’ stock ratings worth following?
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.